Editorials

Promoting cost effective prescribing

In many countries the cost effectiveness of drugs is receiving increasing attention. Rising budgets have heightened concerns about containing costs and whether resources are used efficiently.¹ The need for rigorous examination of cost effectiveness as well as clinical effectiveness has been argued for.^{2 3 4} The message is clear: doctors may prescribe an effective drug to patients who will benefit, but if the drug is not cost effective they may be using resources that would produce greater benefit for other patients for the same cost.

Expensive drugs require the use of limited resources, which, once deployed are not available for other activities that may bring greater benefits for patients. When an expensive drug is shown to be cost effective, however, its use is justified by the additional benefits it brings. To use scarce resources efficiently the careful and explicit measurement of the value of what is given up (the . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Promoting cost effective prescribing

Adrian Towse and Nicholas Wells
BMJ 1995 311: 126. [Extract] [Full Text]

More trials from general practice are needed

Dennis M Tracey
BMJ 1995 311: 126. [Extract] [Full Text]

This article has been cited by other articles:

• Maynard, A., Bloor, K. (2003). Dilemmas In Regulation Of The Market For Pharmaceuticals. Health Aff (Millwood) 22: 31-41 [Abstract] [Full text]  
• Hill, S. R., Mitchell, A. S., Henry, D. A. (2000). Problems With the Interpretation of Pharmacoeconomic Analyses: A Review of Submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 283: 2116-2121 [Abstract] [Full text]  
• Pringle, M., Jones, J. (1998). Preventing ischaemic heart disease in one general practice: from one patient, through clinical audit, needs assessment, and commissioning into quality improvement • Commentary: Clinical and economic perspectives have to be integrated when selecting priorities for intervention. BMJ 317: 1120-1124 [Full text]  
• Ernst, E. (1997). Integrating complementary medicine?. The Journal of the Royal Society for the Promotion of Health 117: 285-286  
• Freemantle, N., Drummond, M. (1997). Should Clinical Trials With Concurrent Economic Analyses Be Blinded?. JAMA 277: 63-64 [Abstract]  
• Dorman, P. J., Sandercock, P. A.G. (1996). Considerations in the Design of Clinical Trials of Neuroprotective Therapy in Acute Stroke. Stroke 27: 1507-1515 [Full text]  
• Towse, A., Wells, N. (1995). Promoting cost effective prescribing. BMJ 311: 126b-126 [Full text]  
• Tracey, D. M (1995). More trials from general practice are needed. BMJ 311: 126c-126 [Full text]  
• Henry, D., Hill, S. (1995). Comparing treatments. BMJ 310: 1279-1279 [Full text]